Strontium and zoledronate hydroxyapatites graded composite coatings for bone prostheses

Current implant coatings struggle to balance bone growth and resorption. While strontium and zoledronate have separate benefits in bone health, their combined effects remain unclear. Prior research has shown strontium supports osteoblast activity and zoledronate inhibits osteoclasts. However, no prior work had resolved how these effects interact when applied together on implant surfaces. This gap motivated the exploration of combined strontium and zoledronate coatings. Understanding their synergistic potential could improve implant longevity. The need for graded compositions to modulate biological responses is well recognized. Yet, no prior work had resolved how to apply these materials in gradient forms. This study aimed to address these uncertainties.

The study aimed to investigate the combined effects of strontium and zoledronate in graded composite coatings. Researchers sought to determine how these materials influence bone cell behavior. The specific problem addressed was the lack of coatings that balance bone formation and resorption. The motivation came from the need for implants that promote healing while preventing degradation. The study focused on developing a novel coating technique. It also aimed to evaluate how graded compositions affect osteoblast and osteoclast interactions. The goal was to create a surface that modulates both bone growth and resorption. This approach could lead to implants with improved long-term performance.

The study used Combinatorial Matrix-Assisted Pulsed Laser Evaporation (C-MAPLE) to deposit coatings. This technique allowed for simultaneous vaporization of two distinct material targets. Strontium-substituted hydroxyapatite and zoledronate-modified hydroxyapatite were used. Titanium substrates were chosen for their biocompatibility and use in implants. The resulting thin films displayed consistent crystallinity and granular morphology. Co-cultures of osteoblast-like MG63 cells and human osteoclasts were used. The cells were studied over a 21-day period to assess viability and function. The method enabled modulation of coating composition to evaluate biological outcomes.

Strontium reduced the negative impact of high zoledronate concentrations on osteoblast viability. Both strontium and zoledronate enhanced extracellular matrix deposition in co-cultures. Zoledronate specifically increased type I collagen production in osteoblasts. Strontium led to higher alkaline phosphatase production in the same cells. Zoledronate had a stronger effect on the osteoprotegerin/RANKL ratio. This effect translated into reduced osteoclast proliferation and activity. The graded composition of the coatings allowed for tunable biological responses. These findings suggest the coatings can simultaneously promote bone growth and inhibit resorption.

The study shows that strontium and zoledronate can work together in graded coatings to modulate bone cell behavior. Strontium counteracts zoledronate's negative effects on osteoblast viability. Both materials enhance extracellular matrix deposition in co-cultures. Zoledronate promotes collagen production, while strontium boosts alkaline phosphatase. The graded composition allows for controlled biological responses. Zoledronate's effect on the osteoprotegerin/RANKL ratio is more pronounced than strontium's. This leads to reduced osteoclast activity and proliferation. The C-MAPLE method enables precise modulation of coating composition for desired outcomes.